Treatment for hemophilia A consists of injecting the missing Factor VIII by I.V. to prevent or stop the bleeding.
A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.

The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by the Bethesda assay or modified Nijmegen Bethesda and is expressed in BU.
1BU neutralizes 50% of the activity of FVIII for hemophilia A.

- 25 cryotubes x 0.5 mL of frozen plasma

CRYOcheck™ Factor VIII Inhibitor Kit
Factor IX Inhibitor Plasma Negative Control
Factor IX Inhibitor Plasma Weak Control
Factor VIII Inhibitor Plasma
Factor VIII Inhibitor Plasma HCV neg
Factor VIII Inhibitor Plasma Weak Control